Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Chardan Capital lifted their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $82.00 in a research report on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $110.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 14th. The Goldman Sachs Group increased their target price on shares of Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the company a "buy" rating in a research report on Monday. Piper Sandler decreased their target price on shares of Arrowhead Pharmaceuticals from $89.00 to $72.00 in a report on Wednesday, May 11th. Finally, StockNews.com raised shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday, May 23rd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $70.83.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR traded up $1.06 on Monday, reaching $47.02. The stock had a trading volume of 1,070,255 shares, compared to its average volume of 793,531. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.37 and a quick ratio of 3.37. The firm has a fifty day moving average of $37.58 and a two-hundred day moving average of $41.73. Arrowhead Pharmaceuticals has a 1-year low of $26.81 and a 1-year high of $84.83. The company has a market cap of $4.97 billion, a P/E ratio of -31.77 and a beta of 1.37.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.17). Arrowhead Pharmaceuticals had a negative net margin of 61.58% and a negative return on equity of 36.05%. The business had revenue of $32.41 million during the quarter, compared to analyst estimates of $52.61 million. During the same period last year, the business earned ($0.29) earnings per share. The business's quarterly revenue was down 29.4% compared to the same quarter last year. On average, equities research analysts anticipate that Arrowhead Pharmaceuticals will post -1.03 EPS for the current year.